Chai Discovery announced a collaboration with Roche on November 5, 2026. Roche will use Chai’s AI models and platform across several drug-discovery programs in its therapeutic areas.
The companies did not disclose targets, program count, financial terms, or timelines. The announcement describes a research collaboration, not a clinical-stage drug or a disclosed development candidate.
The deal adds to Chai’s growing list of pharmaceutical collaborations in 2026, following partnerships with companies including Eli Lilly, Pfizer, Novartis, Bristol Myers Squibb, and GSK.
The pact also fits Roche’s broader push into AI for research and drug development. The key test will be whether AI-designed molecules can be experimentally validated and advance into development.
Sources:
Chai Discovery Announces Collaboration with Roche in AI ...
Chai's AI dealmaking streak rolls on with Roche drug discovery pact
Roche Will Run Chai Discovery's AI Design Models in Drug Programs
Roche Partners with Chai Discovery to Leverage AI Models in Drug ...
Roche Partners with Chai Discovery to Deploy Chai-3 Across Global Therapeutic Pipelines
Roche partners with Chai Discovery to speed… · AGI Hunt
Chai Discovery and Roche Partner to Advance AI-Driven Drug ...
Chai Discovery (@chaidiscovery) / X
Articles published by Chai Discovery
Chai Adds Roche to Its Expanding AI Drug Discovery Network